Dosage protocol · Brain Health & Nootropics
PE-22-28 10 mg
Typical daily range: 50–200 µg once daily (gradual titration over 8–16 weeks).
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 50–200 µg once daily (gradual titration over 8–16 weeks).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.
Reconstitution
PE-22-28 dosage chart
| Week | Dose | Draw |
|---|---|---|
| Weeks 1–2 | 50 µg | 1.5 units0.015 mL |
| Weeks 3–4 | 100 µg | 3 units0.03 mL |
| Weeks 5–8 | 100 µg | 3 units0.03 mL |
| Weeks 9–12 (Optional) | 150 µg | 4.5 units0.045 mL |
| Weeks 13–16 (Optional) | 200 µg | 6 units0.06 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
PE-22-28 is a research-stage synthetic peptide fragment discussed in the literature as an analog of spadin, a peptide originally identified from the propeptide of sortilin. Spadin itself was first described in 2010 as a blocker of the TREK-1 potassium channel with antidepressant-like effects in rodents, and PE-22-28 (also written PE 22-28) is a shortened variant studied in that same research lane.[1]
PE-22-28 is not a marketed or clinically established medication. It exists almost entirely within preclinical neuroscience research on ion-channel pharmacology and mood-related animal models, rather than as a characterized human therapeutic.[2]
Benefits & side effects
Nearly all relevant evidence is preclinical and rodent-based. TREK-1 knockout mice and spadin-treated animals have shown antidepressant-like behavior in standard rodent screening tests, alongside mechanistic findings related to hippocampal neurogenesis pathways also studied in conventional antidepressant research.[9]
Under the specific name PE-22-28, public searches of PubMed and ClinicalTrials.gov do not identify a meaningful registered human trial record, and no published human efficacy or pharmacokinetic data exist under this name.[3] Claims about mood, memory, or brain-support benefits in people are therefore extrapolated from spadin/TREK-1 animal research rather than demonstrated directly for PE-22-28, and should be read as hypothesis, not established fact.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.